8-K: Allurion Technologies Reports Strong Q2 Revenue Growth and Business Update

Allurion Technologies announced a 25% sequential revenue increase in Q2 2024, alongside record procedure volume and a business update.

Summary

• Allurion Technologies reported a second quarter revenue of $11.8 million, a 25% increase compared to the first quarter of 2024.
• The company's loss from operations decreased by 30% year-over-year, and by 44% when excluding one-time financing costs.
• Procedure volume, measured by new app users, grew by 12% year-over-year, with over 10,000 Allurion balloon placements for the second consecutive quarter.
• Full-year 2024 revenue guidance has been updated to between $40 million and $45 million.
• A third-party study showed active patients gained an average of 5.6% lean mass while averaging 14% weight loss on the Allurion Program.
• The company completed a public offering and concurrent private placement on July 1, 2024, generating approximately $22.0 million in gross proceeds.
• Allurion is working towards a plan to achieve profitability by the end of next year.
• The company launched GLP-1 drug support for Coach Iris, its AI-powered weight loss coach.
• The French regulatory authority, ANSM, has suspended sales of the Allurion Balloon in France, and the company is working on a remediation plan.
• The company expects procedure volume growth to be between 10% and 15% for the full year 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive aspects like strong sequential revenue growth and reduced operating losses, the negative impact of the French regulatory issues and the revised revenue guidance temper the overall sentiment. The company is making progress but faces significant challenges.

Positives

• Allurion experienced strong sequential revenue growth of 25% in the second quarter of 2024.
• The company achieved record procedure volume, with over 10,000 balloon placements for the second consecutive quarter.
• Operating losses were significantly reduced, indicating improved cost management.
• The company successfully raised $22 million through a public offering and private placement, strengthening its balance sheet.
• A third-party study demonstrated positive patient outcomes, including lean mass gain and weight loss.
• The launch of GLP-1 drug support for Coach Iris expands the company's digital platform capabilities.
• The company is on track to complete the AUDACITY trial by the end of the year.

Negatives

• The French regulatory authority has suspended sales of the Allurion Balloon in France, impacting revenue.
• The company has revised its full-year 2024 revenue guidance to $40-$45 million, reflecting slower growth than initially expected.
• Year-over-year revenue decreased from $13 million in Q2 2023 to $11.8 million in Q2 2024.
• The company experienced macroeconomic headwinds in certain markets, leading to lower re-order rates.
• There were reductions in sales to certain accounts to manage credit risk.

Risks

• The suspension of sales in France poses a significant risk to revenue and market presence.
• Macroeconomic headwinds and slower growth in certain regions may impact future financial performance.
• The company faces risks related to regulatory approvals and commercialization of its products.
• The competitive landscape and the impact of GLP-1 drugs could affect market demand.
• There are risks associated with the company's ability to maintain its listing on the New York Stock Exchange.
• The company is subject to general economic, political, and business conditions.

Future Outlook

Allurion updated its full-year 2024 revenue guidance to between $40 million and $45 million and expects procedure volume growth to be between 10% and 15%. The company is working towards a plan to achieve profitability by the end of next year.

Management Comments

• After restructuring our business at the end of 2023, the entire Allurion team executed at a high level and posted a second consecutive quarter of sequential revenue growth, record procedure volume, and significant improvements in operating income, said Dr. Shantanu Gaur, Chief Executive Officer.
• With a balance sheet strengthened from our recent public offering, we now believe we have the cash runway to execute through significant milestones and are working toward a plan to achieve profitability by the end of next year.
• We launched GLP-1 drug support for Coach Iris, advancing our vision to create a verticalized, conversational AI agent for weight loss that any patient can use, Dr. Gaur continued.
• We believe the 24/7, 360-degree support that our digital platform provides enables best-in-class outcomes, including improvements in body composition and muscle mass that have proven difficult to achieve using other modalities.
• The safety of the Allurion Balloon has been well-established in 20 peer-reviewed publications and over 150,000 patients we estimate that we have treated commercially, Dr. Gaur continued.
• We have adjusted our guidance to take into account the disruption of sales in France, more conservative assumptions on inventory stocking, and macroeconomic headwinds in other regions that we believe will lead to slower growth than originally expected in the second half of 2024, said Dr. Gaur.

Industry Context

This announcement comes amid a growing focus on weight loss solutions and the increasing popularity of GLP-1 drugs. Allurion's expansion into GLP-1 support with its AI platform positions it to capitalize on these trends, while the regulatory issues in France highlight the challenges in the medical device market.

Comparison to Industry Standards

• Allurion's 25% sequential revenue growth is strong compared to many medical device companies, but the year-over-year decrease indicates challenges.
• The 12% year-over-year procedure volume growth is a positive sign, but the updated revenue guidance suggests a more conservative outlook.
• The reduction in operating losses is a positive trend, but the company still needs to achieve profitability.
• The suspension of sales in France is a significant setback, especially when compared to competitors who have not faced similar regulatory issues.
• The company's focus on digital health and AI-powered support aligns with industry trends, but the success of these initiatives remains to be seen.
• Competitors in the weight loss market include companies offering surgical, medical, and nutritional solutions, and Allurion's performance needs to be evaluated against these alternatives.

Stakeholder Impact

• Shareholders will be impacted by the revised revenue guidance and the suspension of sales in France.
• Employees may be affected by the company's cost reduction initiatives and restructuring efforts.
• Customers may experience disruptions in access to the Allurion Balloon in France.
• Suppliers may be affected by changes in inventory stocking and re-order rates.
• Creditors may be impacted by the company's debt refinancing and financial performance.

Next Steps

• Allurion will focus on implementing a remediation plan to resume sales in France.
• The company will continue to expand the capabilities of its digital platform, including Coach Iris.
• Allurion will work towards achieving profitability by the end of next year.
• The company will continue to monitor and manage macroeconomic headwinds and their impact on the business.

Key Dates

Keywords

Allurion, weight loss, gastric balloon, revenue, procedure volume, financial results, GLP-1, Coach Iris, digital health, obesity, ANSM, France, public offering